Lamivudine

Generic Name: Lamivudine

Brand Names: Cimduo, Combivir, Delstrigo, Dovato, Epivir, Epivir Hbv, Epzicom, Kivexa, Symfi, Triumeq, Trizivir, Zeffix, Lamivudine Teva Pharma B.V., Lamivudine Teva

Drug Type: Small Molecule

Chemical Formula: C_₈H_₁₁N_₃O_₃S

CAS Number: 134678-17-4

Unique Ingredient Identifier: 2T8Q726O95

Background: A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).

Indication: For the treatment of HIV infection and chronic hepatitis B (HBV).

Associated Conditions: Chronic Hepatitis B Infection, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Associated Therapies: -

Clinical Trials

A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection

Phase 4

Completed

Conditions: Chronic Hepatitis B

Interventions: Drug: Entecavir
Drug: Lamivudine
Drug: Lamivudine Placebo
Drug: Entecavir Placebo

First Posted Date: 2006-10-27

Last Posted Date: 2014-11-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 122

Registration Number: NCT00393484

Locations: 🇰🇷
Local Institution, Seoul, Korea, Republic of

A Randomized Controlled Trial of Lamivudine in Acute Hepatitis B

Phase 4

Completed

Conditions: Hepatitis B

First Posted Date: 2006-09-26

Last Posted Date: 2006-09-26

Lead Sponsor: Maulana Azad Medical College

Registration Number: NCT00380614

Locations: 🇮🇳
G.B. Pant Hospital, New Delhi, Delhi, India

Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A

Phase 2

Completed

Conditions: Human Immunodeficiency Virus (HIV)-1 Infection

First Posted Date: 2006-09-25

Last Posted Date: 2023-08-14

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 4

Registration Number: NCT00380159

Locations: 🇪🇸
Clinical Trial Site, Madrid, Spain

A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone

Phase 4

Completed

Conditions: CHRONIC HEPATITIS B

First Posted Date: 2006-07-20

Last Posted Date: 2020-03-03

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 100

Registration Number: NCT00354653

Locations: 🇮🇷
GSK Clinical Trials Call Center, Tehran, Iran, Islamic Republic of

Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: Elvucitabine
Drug: Lamivudine
Drug: Tenofovir
Drug: Efavirenz

First Posted Date: 2006-07-10

Last Posted Date: 2023-08-30

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 76

Registration Number: NCT00350272

Locations: 🇵🇷
Clinical Trial Site, San Juan, Puerto Rico

Antiretroviral Therapy for Advanced HIV Disease in South Africa

Phase 4

Completed

Conditions: HIV

Interventions: Drug: Zidovudine
Drug: Stavudine
Drug: Lamivudine
Drug: Didanosine
Drug: Lopinavir/Ritonavir
Drug: Efavirenz

First Posted Date: 2006-06-21

Last Posted Date: 2013-05-21

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 1771

Registration Number: NCT00342355

Locations: 🇿🇦
Mtubatuba SIckbay, Kwazulu-Natal, South Africa
🇿🇦
Umtata Sickbay, Eastaern Cape, South Africa
🇿🇦
South African Military Health Services (SAMHS), Centurion, South Africa

and more 4 locations

Drug Levels of Tablet and Liquid Forms of Lamivudine, Nevirapine, and Stavudine in HIV Infected Thai Children

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Lamivudine, nevirapine, and stavudine fixed-dose tablet
Drug: Lamivudine
Drug: Nevirapine
Drug: Stavudine

First Posted Date: 2006-04-07

Last Posted Date: 2021-11-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 44

Registration Number: NCT00312091

Locations: 🇹🇭
Siriraj Hospital Mahidol University CRS, Bangkok, Ratchathewi, Thailand
🇹🇭
Chiang Mai University Pediatrics-Obstetrics CRS, Chiang Mai, Thailand
🇹🇭
Chonburi Hosp. CRS, Chonburri, Thailand

and more 1 locations

Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Lamivudine
Drug: Elvucitabine

First Posted Date: 2006-04-07

Last Posted Date: 2023-08-25

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 20

Registration Number: NCT00312039

Locations: 🇺🇸
Clinical Trial Site, Cincinnati, Ohio, United States

Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: Lamivudine
Drug: Lopinavir/ritonavir
Drug: Nevirapine
Drug: Zidovudine

First Posted Date: 2006-03-27

Last Posted Date: 2017-04-13

Lead Sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group

Target Recruit Count: 452

Registration Number: NCT00307151

Locations: 🇿🇲
George Clinic CRS, Lusaka, Zambia
🇿🇼
UZ-College of Health Sciences, Harare, Zimbabwe
🇮🇳
BJ Medical College CRS, Pune, Maharashtra, India

and more 7 locations

Trial to Evaluate Steady State Pharmacokinetic Parameters, Efficacy and Safety of Nevirapine in Antiretroviral Drug naïve Pediatric Patients

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2006-01-10

Last Posted Date: 2013-10-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 123

Registration Number: NCT00273975

Locations: 🇿🇦
Boehringer Ingelheim Investigational Site, Tygerberg, South Africa
🇿🇦
Groote Schuur Hospital, Cape Town, South Africa

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy